Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

被引：10

作者：

Wiser H.J. ^{[1
]}

Köhler T.S. ^{[1
]}

机构：

[1] Division of Urology, Southern Illinois University School of Medicine, Springfield, IL 62794

来源：

Current Urology Reports | 2010年 / 11卷 / 4期

关键词：

5-alpha-reductase inhibitor; Alpha-1-adrenergic antagonist; Benign prostatic hyperplasia; Erectile dysfunction; Holmium laser enucleation of the prostate; Lower urinary tract symptoms; Open prostatectomy; Phosphodiesterase inhibitor; Prostate photovaporization; Retrograde ejaculation; Transurethral resection of the prostate;

D O I：

10.1007/s11934-010-0112-x

中图分类号：

学科分类号：

摘要：

Lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) and the treatment of these conditions are commonly associated with sexual dysfunction. The effects on sexual function of common medical and surgical therapies used in the treatment of LUTS/BPH are reviewed. Also discussed is the emerging use of phosphodiesterase inhibitors in the treatment of LUTS/BPH. © Springer Science+Business Media, LLC 2010.

引用

页码：228 / 235

页数：7

共 39 条

[1]

AUA Guidelines on Management of Benign Prostatic Hyperplasia, (2003)

[2]

Price D.T., Schwinn D.A., Lomasney J.W., Et al., Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate, J Urol, 150, pp. 546-551, (1993)

[3]

Roehrborn C.G., Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms, Rev Urol, 11, SUPPL 1, (2009)

[4]

Hellstrom W.J., Sikka S.C., Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers, J Urol, 176, pp. 1529-1533, (2006)

[5]

Nagai A., Hara R., Yokoyama T., Et al., Ejaculatory dysfunction caused by the new α-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography, Int J Urol, 15, pp. 915-918, (2008)

[6]

Hisasue S., Furuya R., Itoh N., Et al., Ejaculatory disorder caused by α-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission, Int J Urol, 13, pp. 1311-1316, (2006)

[7]

Kobayashi K., Masumori N., Hisasue S., Et al., Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers, J Sex Med, 5, pp. 2185-2190, (2008)

[8]

Goldstein I., Oral phentolamine: An alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction, Int J Impot Res, 12, SUPPL 1, (2000)

[9]

Kirby R.S., Roehrborn C., Boyle P., Et al., Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial, Urology, 61, pp. 119-126, (2003)

[10]

Lepor H., Williford W.O., Barry M.J., Et al., The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia, N Engl J Med, 335, pp. 533-539, (1996)

← 1 2 3 4 →